Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Intellia Therapeutics (NTLA) shares plummeted over 45% after its lead gene-editing candidate, nex-z, for ATTR amyloidosis, encountered a significant setback with a Phase 3 trial pause due to a patient experiencing severe liver damage. This development casts serious doubt on the drug's safety and its substantial projected sales of $12 billion by 2028, despite the company also progressing with Lonvo-z, another promising Phase 3 candidate for hereditary angioedema. The incident highlights the inherent high risks in clinical-stage biotech investments, leaving the stock's outlook highly uncertain, even with previous analyst optimism and Cathie Wood's backing.

Analysis

Intellia Therapeutics (NTLA) shares plunged over 45% following a significant setback in its lead gene-editing candidate, nex-z, which saw its Phase 3 trials paused due to a patient experiencing severe liver damage. This adverse event immediately casts substantial doubt on the drug's safety profile and its path to regulatory approval, despite previous analyst optimism and Cathie Wood's long-term investment. The market reaction reflects a sharp repricing of the company's risk profile.

The nex-z setback critically impacts its projected $12 billion in sales by 2028 for transthyretin (ATTR) amyloidosis, a figure already deemed optimistic given the high costs and reimbursement challenges of gene therapies. While Intellia's other promising candidate, Lonvo-z for hereditary angioedema, continues in Phase 3 with a $5 billion sales projection, the larger commercial opportunity of nex-z now faces considerable uncertainty.

This incident underscores the inherent volatility and elevated risks associated with investing in clinical-stage biotechnology companies, where pipeline success is paramount. The company's ambitious sales forecasts for both candidates also face scrutiny regarding market access and payer acceptance for high-priced gene-editing treatments, suggesting potential overestimation of market penetration.

Consequently, the stock's outlook remains highly uncertain, with potential for further downside if nex-z's safety issues persist, even as Lonvo-z progresses. This situation highlights the binary nature of clinical trial outcomes and their profound impact on biotech valuations.

Key Decisions for Investors

• Investors should exercise extreme caution due to the significant clinical and regulatory risks now associated with the nex-z program.
• Closely monitor upcoming announcements regarding the nex-z liver damage investigation, potential trial resumption, and Lonvo-z's Phase 3 data and regulatory submission.
• Re-evaluate the company's ambitious sales projections for both candidates, considering potential headwinds from high gene therapy costs and reimbursement challenges.
• For risk-tolerant investors considering a position, initiate with a very small allocation, acknowledging the binary nature of clinical-stage biotech outcomes.